Newsroom | 18263 results

DUBLIN--(BUSINESS WIRE)--The "Fallopian Tube Cancer Market - A Global and Regional Analysis: Focus on Type, Treatment Type, End User, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The global fallopian tube cancer market is being driven by several key factors. Rising awareness and early screening initiatives, supported by public health campaigns and improved diagnostic imaging technologies, are enabling earlier detection of gynaecologic cance...

DUBLIN--(BUSINESS WIRE)--The "DNA Methylation Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The global DNA methylation market, valued at an estimated USD 1.64 billion in 2024, is anticipated to experience robust growth, reaching USD 5.52 billion by 2033. This represents a compound annual growth rate (CAGR) of 14.73% from 2025 to 2033. Market expansion is predominantly driven by the increasing prevalence of cancer and other chronic conditions. According to the Nat...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results. “The recent FDA approval of REDEMPLO, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), is a transformational milestone for Arrowhead. REDEMPLO is the first and on...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of two abstracts for oral presentation, three abstracts for poster presentation and one abstract for online publication at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 6-9, 2025, in Orlando, Florida. BostonGene will exhibit in booth #1581. “The research we are presenting highlights the cri...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved dosing in Cohort 8 of ENDEAVOR (Study 9001-103). The purpose of Cohort 8 is to evaluate the use of an enhanced immunosuppressive regimen as part of treatment with ELEVIDYS (delandistrogene moxeparvovec-rokl) for non-ambulant individuals with Duchenne muscular dystrophy. Data from Coh...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET. A webcast of the presentation can be accessed on the "Events and Presentations” page under the “Investors” section of the enGene website at www.engene.com and wil...

DUBLIN--(BUSINESS WIRE)--The "Rare NRG1 Fusion Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global rare NRG1 fusion market is expected to witness substantial growth, expanding significantly from 2024 and projected to register a strong compound annual growth rate (CAGR) through 2035. This growth is mainly attributed to increasing awareness about NRG1 fusions and...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference in Miami. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 2, at 7:55 a.m. ET and host investor meetings. A webcast of the p...

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia will present new data demonstrating the utility of MammaPrint and BluePrint in patients with HR+HER2– early breast cancer at SABCS 2025....

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference (Fireside Chat) Tuesday, December 2, 2025 (12:30 p.m. ET) About Arcturus Founded in 2013 and based i...